ArticleTherapeutics and clinical risk management2008
Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations.
Article in Therapeutics and clinical risk management, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Comparison of extrafine and non-extrafine inhaled corticosteroids/long-acting β2-agonists as maintenance and reliever therapy in asthma: a randomized open-label crossover trial.The Korean journal of internal medicine · 2025Trial
- Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD.BMC pulmonary medicine · 2014Trial
- Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.Journal of aerosol medicine and pulmonary drug delivery · 2010Trial
- Comparison of Two pMDIs in Adult Asthmatics: A Randomized Double-Blind Double-Dummy Clinical Trial.Tuberculosis and respiratory diseases · 2022Article
- Drug interaction and chronic obstructive respiratory disorders.Current research in pharmacology and drug discovery · 2021Review
- Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways.Respiratory research · 2018Article
- Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.Journal of aerosol medicine and pulmonary drug delivery · 2016Review
- Patient perspectives on fluticasone-vilanterol versus other corticosteroid combination products for the treatment of asthma.Patient preference and adherence · 2016Review
- Use of ICS/LABA (extra-fine and non-extra-fine) in elderly asthmatics.Therapeutics and clinical risk management · 2016Review
- Asthma control: the right inhaler for the right patient.Advances in therapy · 2015Review
- Small airways dysfunction in asthma: evaluation and management to improve asthma control.Allergy, asthma & immunology research · 2014Review
- Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.Patient related outcome measures · 2014Review
- Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options.Patient preference and adherence · 2010Article
- New pharmacologic perspectives in pneumology: beclomethasone-formoterol extrafine.The open respiratory medicine journal · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drugs for asthma and other chronic obstructive diseases of the lungs should be preferably delivered by the inhalation route to match therapeutic effects with low systemic exposure. Inhaled drugs are delivered to the lungs via different devices, mainly metered dose inhalers and dry powder inhalers, each characterized by specific inhaler technique and instructions for use. The patient-device interaction is part of the prescribed therapy and can have a relevant impact on adherence and clinical outcomes. The most suitable device should be considered for each patient to assure the correct drug intake and adherence to the prescribed therapy. The development of new drugs/devices in the past decades improved the compliance with inhaler and possibly drug delivery to the bronchi. The present review focuses on the recently developed beclomethasone/formoterol extrafine fixed combination and technical aspects of drug delivery to the lungs in patient's perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.